Loading
Total declarations
Company
▲ Purchases (274 ops.)
▼ Sales (0 ops.)
Latest filing published 12 Oct 2026 for Dawnrays Pharmaceutical (Holdings) Ltd., €6,559.
Filing timeline
BuySaleLi Kei Ling
Insider track record
Disclosed buys
274
Disclosed sells
0
Signal history
Closed purchases
Market purchases
274
Positive at T+90
55%
Median T+90
+1.4%
Based on 51 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -3.6%Entry HK$0.98 · Close 23 Oct 2026 HK$0.94
- -6.0%Entry HK$1.00 · Close 23 Oct 2026 HK$0.94
- -19.1%Entry HK$1.23 · Close at T+365 HK$1.00
- -9.4%Entry HK$1.17 · Close at T+365 HK$1.06
- -4.3%Entry HK$1.17 · Close at T+365 HK$1.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Li Kei Ling: trading record in brief
Li Kei Ling (chief executive) discloses dealings in Dawnrays Pharmaceutical (Holdings) Ltd. to HKEX. In total, 274 filings cover trades dated from 23 October 2017 to 9 October 2026.
The open-market record is one-sided, with 274 purchases worth €3.9M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2026 to date brings 20 purchases and no sales.
A typical purchase (the median) is worth €8,490. Measured against the company's value, the median purchase equals 0.0045% of market capitalisation, across 20 purchases where it is known. 242 out of 271 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 51 purchases old enough to measure, the stock rose over the following 90 days in 55% of cases; the median change was +1.4%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 12 October 2026, the filings show an open-market purchase worth €6,559 in Dawnrays Pharmaceutical (Holdings) Ltd. Between a trade and the moment it shows up on HKEX, the median delay is 1 day. That lag is the time during which only the insider knows about the trade. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Companies and markets linked to Li Kei Ling
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations53 total
60,000 shares@ HK$0.9650.0040% mcap4.1% of flowShareXHKGHKEX:DA20261009E00684
Canonical exit: 5 Jan 2027 (T+90)
60,000 shares@ HK$0.960.0040% mcap4.1% of flowShareXHKGHKEX:DA20261009E00691
Canonical exit: 7 Jan 2027 (T+90)
84,000 shares@ HK$0.96670.0056% mcap6.3% of flowShareXHKGHKEX:DA20261007E00012
Canonical exit: 3 Jan 2027 (T+90)
172,000 shares@ HK$0.9730.011% mcap13.7% of flowShareXHKGHKEX:DA20261002E00163
Canonical exit: 29 Dec 2026 (T+90)
96,000 shares@ HK$0.9760.0064% mcap8.9% of flowShareXHKGHKEX:DA20260930E00012
Canonical exit: 28 Dec 2026 (T+90)
96,000 shares@ HK$0.9750.0063% mcap8.8% of flowShareXHKGHKEX:DA20260930E00011
Canonical exit: 27 Dec 2026 (T+90)
76,000 shares@ HK$0.9850.0051% mcap8.5% of flowShareXHKGHKEX:DA20260924E00322
Canonical exit: 22 Dec 2026 (T+90)
92,000 shares@ HK$0.9750.0061% mcap10.2% of flowShareXHKGHKEX:DA20260924E00310
Canonical exit: 21 Dec 2026 (T+90)
64,000 shares@ HK$0.97880.0042% mcap7.1% of flowShareXHKGHKEX:DA20260922E00293
Canonical exit: 20 Dec 2026 (T+90)
104,000 shares@ HK$0.9950.0071% mcap0.3% of flowShareXHKGHKEX:DA20260911E00701
Canonical exit: 9 Dec 2026 (T+90)
60,000 shares@ HK$0.990.0040% mcap6.7% of flowShareXHKGHKEX:DA20260905E00055
Canonical exit: 3 Dec 2026 (T+90)
104,000 shares@ HK$1.000.0069% mcap11.7% of flowShareXHKGHKEX:DA20260905E00054
Canonical exit: 2 Dec 2026 (T+90)
72,000 shares@ HK$1.000.0049% mcap8.3% of flowShareXHKGHKEX:DA20260626E00345
Canonical exit: 23 Sept 2026 (T+90)
36,000 shares@ HK$1.130.0027% mcap4.6% of flowShareXHKGHKEX:DA20260514E00647
Canonical exit: 12 Aug 2026 (T+90)
52,000 shares@ HK$1.150.0039% mcap6.7% of flowShareXHKGHKEX:DA20260508E00494
Canonical exit: 5 Aug 2026 (T+90)
8,000 shares@ HK$1.120.0006% mcap1.0% of flowShareXHKGHKEX:DA20260423E00020
Canonical exit: 20 Jul 2026 (T+90)
44,000 shares@ HK$1.120.0032% mcap5.5% of flowShareXHKGHKEX:DA20260416E00051
Canonical exit: 14 Jul 2026 (T+90)
20,000 shares@ HK$1.130.0015% mcap2.5% of flowShareXHKGHKEX:DA20260415E00001
Canonical exit: 12 Jul 2026 (T+90)
40,000 shares@ HK$1.140.0030% mcap5.1% of flowShareXHKGHKEX:DA20260403E00004
Canonical exit: 30 Jun 2026 (T+90)
84,000 shares@ HK$1.090.0060% mcap10.5% of flowShareXHKGHKEX:DA20260331E00415
Canonical exit: 28 Jun 2026 (T+90)
8,000 shares@ HK$1.170.0% of flowShareXHKGHKEX:DA20251126E00406
Canonical exit: 22 Feb 2026 (T+90)
60,000 shares@ HK$1.180.2% of flowShareXHKGHKEX:DA20251113E00001
Canonical exit: 9 Feb 2026 (T+90)
60,000 shares@ HK$1.200.2% of flowShareXHKGHKEX:DA20251107E00494
Canonical exit: 4 Feb 2026 (T+90)
52,000 shares@ HK$1.220.2% of flowShareXHKGHKEX:DA20251105E00009
Canonical exit: 1 Feb 2026 (T+90)
60,000 shares@ HK$1.210.2% of flowShareXHKGHKEX:DA20251101E00002
Canonical exit: 28 Jan 2026 (T+90)
25 of 53 declarations
